arrow
F

Fernando Ramos Lopez

University of Oxford
H指数:18
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection

重复受控人体疟疾感染后对 *Plasmodium vivax* 的临床免疫发展

2025-09-250
OAAI
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK : a dose-escalation, randomised, controlled, phase 1 trial
2024-08-018
OAAI
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults
2024-07-063
OAAI
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
2024-05-016
OAAI
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, doubleblind, randomised, phase 3 trial

疟疾候选疫苗R21/match-m在非洲儿童中的安全性和有效性: 一项多中心,双盲,随机,3期试验

LANCET
IF88.5
2024-02-0168
OAAI
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

布基纳法索儿童R21/Matrix-M疫苗对临床疟疾的疗效和免疫原性: 1/2b期随机对照试验

2022-12-01142
OAAI
Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics
2022-08-226
OAAI
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria
2022-02-0713
OAAI
Controlled human malaria infection with a clone of Plasmodium vivax with high- quality genome assembly
2021-12-0817
OA
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
2021-07-3035
OAAI
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

RH5疫苗接种后人类血液阶段疟疾生长和免疫相关性降低

MED
IF11.8
2021-06-0185
OAAI
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

布基纳法索儿童季节性接种低剂量候选疟疾疫苗R21和佐剂matrix-m的疗效: 一项随机对照试验

LANCET
IF88.5
2021-05-01270
OAAI
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
2020-07-01166
OAAI